Akrevia Therapeutics scores $30 mln Series A

Cambridge, Massachusetts-based Akrevia Therapeutics, a biopharmaceutical company focused on developing immuno-oncology therapeutics, has secured $30 million in Series A financing. F-Prime Capital Partners and Atlas Venture led the round.

ManagersNorth AmericaUSHealthcareBriefs